Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | May 08, 2026 | May 11, 2026 |
| Cerevel Therapeutics Holdings, Inc.CERE · Entity 15182 | President | February 06, 2023 | February 08, 2023 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | September 04, 2025 | September 08, 2025 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director · Chief Executive Officer | October 06, 2026 | October 08, 2026 |
| scPharmaceuticals Inc.SCPH · Entity 74456 | Chief Operating Officer | January 17, 2018 | January 19, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date May 08, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,384 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Grant · Acquired 1,438 · Balance 2,384 F1: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.
Cerevel Therapeutics Holdings, Inc.
Report date February 06, 2023 · Filed February 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.41 · Expires 2033-02-06 | Direct | 114,445 |
Reported balance
After 2023-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-06 · Grant · Acquired 114,445 · Balance 114,445 F1: 25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 29,083 |
Reported balance
After 2023-02-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-06 · Grant · Acquired 29,083 · Balance 29,083 F2: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. F3: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F3: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date.
Pacira BioSciences, Inc.
Report date September 04, 2025 · Filed September 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,039 |
Reported balance
After 2025-09-04 transaction · row 1
1 source rowRow 1 · 2025-09-04 · Sale · Disposed 2,354 · Balance 9,039 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
Rapport Therapeutics, Inc.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 452,245 |
Ending reported balance
After 2026-10-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Sale · Disposed 3,375 · Balance 453,392 F1: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.65 to $32.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 2 · 2026-10-07 · Sale · Disposed 1,147 · Balance 452,245 F1: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.33 to $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Ceesay Family Irrevocable Trust | 81,729 |
Reported balance
Holding disclosure · report date 2026-10-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 81,729 |
| Common StockSEC Table I · non-derivative | IndirectBy Dorothy Ceesay Irrevocable Trust | 20,729 |
Reported balance
Holding disclosure · report date 2026-10-06 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 20,729 |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.65 to $32.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.33 to $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
scPharmaceuticals Inc.
Report date January 17, 2018 · Filed January 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.23 · Expires 2028-01-17 | Direct | 80,971 |
Reported balance
After 2018-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-17 · Grant · Acquired 80,971 · Balance 80,971 F1: The option shares vest over a four-year period, at a rate of 25% on the first anniversary of the grant date, with the remaining option shares vesting in 36 equal monthly installments thereafter, such that the option shares are fully vested on the fourth anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares vest over a four-year period, at a rate of 25% on the first anniversary of the grant date, with the remaining option shares vesting in 36 equal monthly installments thereafter, such that the option shares are fully vested on the fourth anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2026 Filed Oct 8, 2026 20:07 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 1,147 | $30.66 | $35,167.02 |
DisclosureSEC source: 0001193125-26-417919 · ownership.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 452,245 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.33 to $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 20:07 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 3,375 | $32.03 | $108,105.98 |
DisclosureSEC source: 0001193125-26-417919 · ownership.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 453,392 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.65 to $32.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 23, 2026 Filed Sep 24, 2026 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 43 | $41.05 | $1,765.15 |
DisclosureSEC source: 0001193125-26-401017 · ownership.xml · nonDerivative · entry 3 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 456,767 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. Read SEC document |
| September 23, 2026 Filed Sep 24, 2026 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 215 | $39.86 | $8,569.94 |
DisclosureSEC source: 0001193125-26-401017 · ownership.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 456,810 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.57 to $40.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 23, 2026 Filed Sep 24, 2026 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 1,952 | $39.05 | $76,230.09 |
DisclosureSEC source: 0001193125-26-401017 · ownership.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 457,025 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.54 to $39.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 1,069 | $46.01 | $49,189.71 |
DisclosureSEC source: 0001193125-26-386436 · ownership.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 458,977 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.95 to $46.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 7,141 | $45.56 | $325,308.26 |
DisclosureSEC source: 0001193125-26-386436 · ownership.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 460,046 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.94 to $45.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 25, 2026 Filed Aug 26, 2026 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 18,921 | $49.57 | $937,957.49 |
DisclosureSEC source: 0001193125-26-368285 · ownership.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 467,187 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.03 to $50.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 20:35 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 5,794 | $48.62 | $281,721.08 |
DisclosureSEC source: 0001193125-26-346995 · ownership.xml · nonDerivative · entry 5 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 486,108 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.45 to $48.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 20:35 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 19,500 | $48.04 | $936,846.30 |
DisclosureSEC source: 0001193125-26-346995 · ownership.xml · nonDerivative · entry 4 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 491,902 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.45 to $48.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 20:35 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 3,664 | $46.90 | $171,837.20 |
DisclosureSEC source: 0001193125-26-346995 · ownership.xml · nonDerivative · entry 3 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 511,402 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.32 to $47.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:35 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 8,370 | $46.75 | $391,279.92 |
DisclosureSEC source: 0001193125-26-346995 · ownership.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 515,066 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.38 to $47.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:35 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 14,171 | $45.97 | $651,491.89 |
DisclosureSEC source: 0001193125-26-346995 · ownership.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 523,436 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.37 to $46.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 7 | $42.74 | $299.15 |
DisclosureSEC source: 0001193125-26-323637 · ownership.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 537,607 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,203 | $42.11 | $92,761.72 |
DisclosureSEC source: 0001193125-26-323637 · ownership.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 537,614 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.66 to $42.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| July 14, 2026 Filed Jul 15, 2026 20:15 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,729 | $40.57 | $110,722.08 |
DisclosureSEC source: 0001193125-26-304786 · ownership.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 539,817 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.37 to $40.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| July 14, 2026 Filed Jul 15, 2026 20:15 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 5,481 | $39.72 | $217,714.64 |
DisclosureSEC source: 0001193125-26-304786 · ownership.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 542,546 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.36 to $40.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 876 | $40.34 | $35,335.65 |
DisclosureSEC source: 0001193125-26-292519 · ownership.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 548,027 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.26 to $40.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 7,344 | $39.77 | $292,062.07 |
DisclosureSEC source: 0001193125-26-292519 · ownership.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 548,903 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.25 to $40.225, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| May 08, 2026 Filed May 11, 2026 20:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,438 | $177.62 | $255,417.56 |
DisclosureSEC source: 0001100682-26-000062 · form4.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,384 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 00:06 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,100 | $29.80 | $62,572.65 |
DisclosureSEC source: 0001193125-26-059886 · ownership.xml · nonDerivative · entry 4 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Dorothy Ceesay Irrevocable Trust Disclosed balance after: 20,729 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.52 to $30.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F6 · ownership.nature: Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 00:06 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,983 | $29.04 | $86,639.15 |
DisclosureSEC source: 0001193125-26-059886 · ownership.xml · nonDerivative · entry 3 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Dorothy Ceesay Irrevocable Trust Disclosed balance after: 22,829 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F6 · ownership.nature: Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 00:06 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,281 | $29.80 | $67,969.92 |
DisclosureSEC source: 0001193125-26-059886 · ownership.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 556,247 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.56 to $30.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 00:06 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 3,552 | $29.05 | $103,191.28 |
DisclosureSEC source: 0001193125-26-059886 · ownership.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 558,528 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:14 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 428,000 | $0.00 Strike: $27.75 | $0.00 |
DisclosureSEC source: 0001193125-26-037603 · ownership.xml · derivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,000 Underlying: Common Stock · 428,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 00:00 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 5,083 | $26.11 | $132,737.46 |
DisclosureSEC source: 0001193125-26-019820 · ownership.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Dorothy Ceesay Irrevocable Trust Disclosed balance after: 25,812 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.83 to $26.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F4 · ownership.nature: Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 00:00 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 5,833 | $26.12 | $152,333.46 |
DisclosureSEC source: 0001193125-26-019820 · ownership.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 562,080 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.83 to $26.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 21:11 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 515 | $31.04 | $15,985.39 |
DisclosureSEC source: 0001193125-25-324826 · ownership.xml · nonDerivative · entry 6 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Dorothy Ceesay Irrevocable Trust Disclosed balance after: 30,895 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.75 to $31.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F8 · ownership.nature: Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 21:11 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,421 | $30.04 | $72,721.51 |
DisclosureSEC source: 0001193125-25-324826 · ownership.xml · nonDerivative · entry 5 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Dorothy Ceesay Irrevocable Trust Disclosed balance after: 31,410 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F8 · ownership.nature: Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 21:11 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,147 | $28.84 | $61,924.85 |
DisclosureSEC source: 0001193125-25-324826 · ownership.xml · nonDerivative · entry 4 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Dorothy Ceesay Irrevocable Trust Disclosed balance after: 33,831 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F8 · ownership.nature: Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 21:11 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 600 | $31.04 | $18,621.60 |
DisclosureSEC source: 0001193125-25-324826 · ownership.xml · nonDerivative · entry 3 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 567,913 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.78 to $31.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 21:11 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,792 | $30.04 | $83,861.91 |
DisclosureSEC source: 0001193125-25-324826 · ownership.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 568,513 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 21:11 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,441 | $28.84 | $70,393.07 |
DisclosureSEC source: 0001193125-25-324826 · ownership.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 571,305 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 21:27 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,841 | $25.44 | $72,266.52 |
DisclosureSEC source: 0001193125-25-286218 · ownership.xml · nonDerivative · entry 4 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Dorothy Ceesay Irrevocable Trust Disclosed balance after: 35,978 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.23 to $25.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F5 · ownership.nature: Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 21:27 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,242 | $24.91 | $55,849.79 |
DisclosureSEC source: 0001193125-25-286218 · ownership.xml · nonDerivative · entry 3 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Dorothy Ceesay Irrevocable Trust Disclosed balance after: 38,819 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.21 to $25.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F5 · ownership.nature: Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 21:27 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 3,056 | $25.43 | $77,715.00 |
DisclosureSEC source: 0001193125-25-286218 · ownership.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 573,746 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.22 to $25.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 21:27 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,777 | $24.92 | $69,215.61 |
DisclosureSEC source: 0001193125-25-286218 · ownership.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 576,802 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.22 to $25.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 755 | $26.17 | $19,759.94 |
DisclosureSEC source: 0001193125-25-241472 · ownership.xml · nonDerivative · entry 4 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Dorothy Ceesay Irrevocable Trust Disclosed balance after: 41,061 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.08 to $26.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F5 · ownership.nature: Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 4,328 | $25.75 | $111,428.69 |
DisclosureSEC source: 0001193125-25-241472 · ownership.xml · nonDerivative · entry 3 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Dorothy Ceesay Irrevocable Trust Disclosed balance after: 41,816 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.07 to $26.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F5 · ownership.nature: Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 1,186 | $26.14 | $31,001.09 |
DisclosureSEC source: 0001193125-25-241472 · ownership.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 579,579 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.06 to $26.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 4,647 | $25.72 | $119,539.43 |
DisclosureSEC source: 0001193125-25-241472 · ownership.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 580,765 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.06 to $26.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 700 | $27.04 | $18,930.03 |
DisclosureSEC source: 0001193125-25-209062 · ownership.xml · nonDerivative · entry 4 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Dorothy Ceesay Irrevocable Trust Disclosed balance after: 46,144 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.02 to $27.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F5 · ownership.nature: Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 34,885 | $26.30 | $917,541.78 |
DisclosureSEC source: 0001193125-25-209062 · ownership.xml · nonDerivative · entry 3 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Dorothy Ceesay Irrevocable Trust Disclosed balance after: 46,844 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.78 to $26.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F5 · ownership.nature: Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 1,400 | $26.87 | $37,624.30 |
DisclosureSEC source: 0001193125-25-209062 · ownership.xml · nonDerivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 585,412 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.74 to $27.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 20:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 39,435 | $26.30 | $1,037,101.07 |
DisclosureSEC source: 0001193125-25-209062 · ownership.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 586,812 F1 · kind: These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 21:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,354 | $27.19 | $64,005.26 |
DisclosureSEC source: 0001396814-25-000109 · wk-form4_1757367430.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,039 F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:18 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 11,279 | $0.00 Strike: $24.34 | $0.00 |
DisclosureSEC source: 0001396814-25-000086 · wk-form4_1749845900.xml · derivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,279 Underlying: Common Stock · 11,279 shares Expires 2035-06-11 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:18 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 6,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-25-000086 · wk-form4_1749845900.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,393 F1 · shares: Represents restricted stock units that vest on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 2,082 | $135.04 Strike: $135.04 | $281,153.28 |
DisclosureSEC source: 0001127602-25-016733 · form4.xml · derivative · entry 2 Ceesay Abraham · CIK 0001722140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,082 Underlying: Common Stock · 2,082 shares Expires 2035-06-02 F2 · shares: The stock options become exercisable upon the earlier of 6/2/2026 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 946 | $135.04 | $127,747.84 |
DisclosureSEC source: 0001127602-25-016733 · form4.xml · nonDerivative · entry 1 Ceesay Abraham · CIK 0001722140 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 946 F1 · shares: The unvested restricted stock units vest upon the earlier of 6/2/2026 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.